A Phase 1/2 interventional study of Injecting KL002 into the bilateral putamen in Parkinson's Disease (PD) and Advanced Primary PD, sponsored by Kanglin Biotechnology (Hangzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Kanglin Biotechnology (Hangzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Parkinson Disease with a site in China — 129 open to participants now, 136 under way, 3 of them phase 3. Parkinson Disease · China.
Among the 279 studies in Parkinson Disease with a site in China, this one is the 174th largest by planned enrollment of the 211 interventional ones that give a count, is the only one that started in 2027, is one of 10 in phase 1/2, reaches primary completion later than 116 of the 135 other live ones, and was the 279th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →129 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Anhui Medical University · Sites in China
Ages 30–75
Hoffmann-La Roche · Sites in China, United States, Ireland and 2 more countries
Ages 40–85
Shanghai UniXell Biotechnology Co., Ltd · Sites in China
Ages 30–75
Ruijin Hospital · Sites in China
Ages 50–85
Ke Dong, MD · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 28 · Phase 3 23 · Phase 4 11
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 48 across the 211 interventional studies, 215 across the 68 observational. Of the 96 that completed or were terminated, 19 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 279 have an industry lead sponsor. The 10 most frequent:
Kanglin Biotechnology (Hangzhou) Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Kanglin Biotechnology (Hangzhou) Co., Ltd. has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
41 of the studies in Parkinson Disease with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725562Phase 3Zhejiang Vimgreen Pharmaceuticals, Ltd.VG081821AC Tablets for Early to Mid-stage Parkinson's Disease | 2027-10-01 |
| NCT07028632iRegene Therapeutics Co., Ltd.The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | 2026-12 |
| NCT07604116Synusight Biotech (Shanghai) Co., Ltd.A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA | 2026-12 |
| NCT06642454Anhui Medical UniversityA Randomized Double-Blind Active-Controlled Crossover Trial of Respiratory-Gated Versus Non-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease | 2026-12-01 |
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 279 studies in Parkinson Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.
This is an open-label, non-randomized, phase 1/2a single ascending dose study, consisting of Dose Escalation and Dose Expansion parts, to evaluate the safety, tolerability, and efficacy of KL002 in patients with advanced primary Parkinson's disease. Eligible subjects will enter the dose escalation part of the study, receive a single stereotactic intraputaminal administration of KL002, and be followed for 52 weeks in the core study and up to 5 years total in long-term follow-up (LTFU)with safety and efficacy assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Putamen stereotactic injection of low dose of KL002
Genetic: Injecting KL002 into the bilateral putamen
Putamen stereotactic injection of high dose of KL002
Genetic: Injecting KL002 into the bilateral putamen
KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes
Adverse event (AE) incidence
To evaluate AEs by CTCAE 6.0
Time frame: From administration of KL002 to the end of the follow-up within 52 weeks
The incidence rate of DLT events
Determined by the Safety Data Review Committee
Time frame: within 4 weeks
Assessment of motor function
Determined by MDS-UPDRS III. The highest score is 56 points, and the lower the score, the better the recovery situation.
Time frame: within 52 weeks
Assessment of dyskinesia
Determined by UDysRS. The highest score is 104 points, and the lower the score, the better the recovery situation.
Time frame: within 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.
Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kanglin Biotechnology (Hangzhou) Co., Ltd.